Accès gratuit
Volume 65, Numéro 4, Juillet-Août 2010
Page(s) 285 - 290
Section Physiopathologie / Physiopathology
Publié en ligne 21 septembre 2010
  1. CHMP 2008. Guideline on medicinal products for the treatment of Alzheimer’s disease and other dementias.\T1\O55395en.pdf [Google Scholar]
  2. Lathia CD, Amakye D, Dai W, et al. State of the art. The value, qualification, and regulatory use of surrogate end points in drug development. Clinical Pharmacology & Therapeutics 2009; 86 (1): 32-43 [CrossRef] [Google Scholar]
  3. Snider BJ, Fagan AM, Roe C, et al. Cerebrospinal fluid biomarkers and rate of cognitive decline in very mild dementia of the Alzheimer type. Arch Neurol 2009; 66(5): 638-45 [CrossRef] [PubMed] [Google Scholar]
  4. Jack CR, Bernstein MA, Borowski BJ, et al. Update on the magnetic resonance imaging core of the Alzheimer’s disease neuroimaging initiative. Alzheimer’s & Dementia 2010; 6(3): 212-20 [CrossRef] [Google Scholar]
  5. Jagust WJ, Bandy D, Chen K, et al. The Alzheimer’s disease neuroimaging initiative positron emission tomography core. Alzheimer’s & Dementia 2010; 6(3): 221-9 [CrossRef] [Google Scholar]
  6. Walhovd KB, Fjell AM, Brewer J, et al. Combining MR imaging, positron-emission tomography, and CSF biomarkers in the diagnosis and prognosis of Alzheimer disease. American Journal of Neuroradiology 2010; 31: 347-54 [Google Scholar]
  7. Van der Vlies AE, Verwey NA, Bouwman FH, et al. CSF biomarkers in relationship to cognitive profiles in Alzheimer Disease SYMBOL. Neurology 2009; 72(12): 1056-61 [CrossRef] [PubMed] [Google Scholar]
  8. Fagan AM, Mintun MA, Shah AR, et al. Cerebrospinal fluid tau and ptau181 increase with cortical amyloid deposition in cognitively normal individuals: implications for future clinical trials of AD. EMBO Molecular Medicine 2009; 1(8-9): 371-80 [CrossRef] [PubMed] [Google Scholar]
  9. Dubois B, Feldman HH, Jacova C, et al. Research criteria for the diagnosis of Alzheimer’s disease: revising the NINCDS-ADRDA criteria. Lancet 2007; 6: 734-46 [Google Scholar]
  10. Vellas B, Andrieu S, Aisen P, et al. for the Oxford Task Force Group. Biomarkers for Alzheimer’s disease therapeutic trials: The Oxford Task Force. Forthcoming [Google Scholar]